1
|
Fields T, M Bremova T, Billington I, Churchill GC, Evans W, Fields C, Galione A, Kay R, Mathieson T, Martakis K, Patterson M, Platt F, Factor M, Strupp M. N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study. Trials 2023; 24:361. [PMID: 37248494 DOI: 10.1186/s13063-023-07399-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Accepted: 05/22/2023] [Indexed: 05/31/2023] Open
Abstract
BACKGROUND Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative lysosomal disease characterized by multiple symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in various studies, including animal models of NPC, observational clinical case studies, and a multinational, rater-blinded phase IIb clinical trial. Here, we describe the development of a study protocol (Sponsor Code "IB1001-301") for the chronic treatment of symptoms in adult and pediatric patients with NPC. METHODS This multinational double-blind randomized placebo-controlled crossover phase III study will enroll patients with a genetically confirmed diagnosis of NPC patients aged 4 years and older across 16 trial sites. Patients are assessed during a baseline period and then randomized (1:1) to one of two treatment sequences: IB1001 followed by placebo or vice versa. Each sequence consists of a 12-week treatment period. The primary efficacy endpoint is based on the Scale for the Assessment and Rating of Ataxia, and secondary outcomes include cerebellar functional rating scales, clinical global impression, and quality of life assessments. DISCUSSION Pre-clinical as well as observational and phase IIb clinical trials have previously demonstrated that IB1001 rapidly improved symptoms, functioning, and quality of life for pediatric and adult NPC patients and is safe and well tolerated. In this placebo-controlled cross-over trial, the risk/benefit profile of IB1001 for NPC will be evaluated. It will also give information about the applicability of IB1001 as a therapeutic paradigm for other rare and common neurological disorders. TRIAL REGISTRATIONS The trial (IB1001-301) has been registered at www. CLINICALTRIALS gov (NCT05163288) and www.clinicaltrialsregister.eu (EudraCT: 2021-005356-10). Registered on 20 December 2021.
Collapse
Affiliation(s)
- T Fields
- IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford, OX5 1PF, UK.
| | - T M Bremova
- Department of Neurology, Inselspital, University Hospital Bern, and University of Bern, Bern, Switzerland
| | - I Billington
- IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford, OX5 1PF, UK
| | - G C Churchill
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - W Evans
- Niemann-Pick UK, Suite 2, Vermont House, Concord, Tyne and Wear, Washington, NE37 2SQ, UK
- Primary Care Stratified Medicine (PRISM), Division of Primary Care, University of Nottingham, Nottingham, UK
| | - C Fields
- IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford, OX5 1PF, UK
| | - A Galione
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - R Kay
- RK Statistics, Brook House, Mesne Lane, Bakewell, DE45 1AL, UK
| | - T Mathieson
- Niemann-Pick UK, Suite 2, Vermont House, Concord, Tyne and Wear, Washington, NE37 2SQ, UK
- RK Statistics, Brook House, Mesne Lane, Bakewell, DE45 1AL, UK
| | - K Martakis
- Department of Pediatric Neurology, University Children's Hospital (UKGM) and Medical Faculty, Justus Liebig University of Giessen, Giessen, Germany
| | - M Patterson
- Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
| | - F Platt
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - M Factor
- IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford, OX5 1PF, UK
| | - M Strupp
- Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany
| |
Collapse
|
2
|
Zinn N, Werner T, Doce C, Mathieson T, Boecker C, Sweetman G, Fufezan C, Bantscheff M. Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags. J Proteome Res 2021; 20:1792-1801. [PMID: 33621079 DOI: 10.1021/acs.jproteome.0c00900] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Multiplexed quantitative proteomics enabled complex workflows to study the mechanisms by which small molecule drugs interact with the proteome such as thermal proteome profiling (TPP) or multiplexed proteome dynamics profiling (mPDP). TPP measures changes in protein thermal stability in response to drug treatment and thus informs on direct targets and downstream regulation events, while the mPDP approach enables the discovery of regulated protein synthesis and degradation events caused by small molecules and other perturbations. The isobaric mass tags available for multiplexed proteomics have thus far limited the efficiency and sensitivity by which such experiments could be performed. Here we evaluate a recent generation of 16-plex isobaric mass tags and demonstrate the sensitive and time efficient identification of Staurosporine targets in HepG2 cell extracts by recording full thermal denaturation/aggregation profiles of vehicle and compound treated samples in a single mass spectrometry experiment. In 2D-TPP experiments, isothermal titration over seven concentrations per temperature enabled comprehensive selectivity profiling of Staurosporine with EC50 values for kinase targets tightly matching to the kinobeads gold standard assay. Finally, we demonstrate time and condition-based multiplexing of dynamic SILAC labeling experiments to delineate proteome-wide effects of the molecular glue Indisulam on synthesis and degradation rates.
Collapse
Affiliation(s)
- Nico Zinn
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| | - Thilo Werner
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| | - Carola Doce
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| | - Toby Mathieson
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| | - Christine Boecker
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| | - Gavain Sweetman
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| | - Christian Fufezan
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany.,Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 69120 Heidelberg, Germany
| | - Marcus Bantscheff
- Cellzome GmbH, a GSK Company, Meyerhofstr. 1, 69117 Heidelberg, Germany
| |
Collapse
|
3
|
Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, Davis W, Evans W, Flint S, Galione A, Granzer U, Greenfield J, Karl R, Kay R, Lewi D, Mathieson T, Meyer T, Pangonis D, Platt FM, Tsang L, Verburg C, Factor M, Strupp M. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials 2021; 22:84. [PMID: 33482890 PMCID: PMC7821839 DOI: 10.1186/s13063-020-05009-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 12/28/2020] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these rare populations and thereby expedite the approval of promising treatments to address patients' high unmet medical need. Here, we describe the development of an innovative master protocol and primary outcome assessment to investigate the modified amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three separate, multinational, phase II trials for three ultra-rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 gangliosidoses (Tay-Sachs and Sandhoff disease; "GM2"), and ataxia telangiectasia (A-T). METHODS/DESIGN The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations. The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the principal investigator appoints for each patient a primary anchor test (either the 8-m walk test (8MWT) or 9-hole peg test of the dominant hand (9HPT-D)) based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to capture all aspects related to the patient's functional performance. The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout. Blinded to the time point of each video, the raters make an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient's neurological signs and symptoms from video A to video B. To investigate both the symptomatic and disease-modifying effects of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study and 1-year extension phase. DISCUSSION The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but meaningful clinical changes critical to the patients' quality of life (fine-motor skills; gait), and blinds the primary outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment for NPC, GM2, and A-T and can also serve as a new therapeutic paradigm for the development of future treatments for other orphan diseases. TRIAL REGISTRATION The three trials (IB1001-201 for Niemann-Pick disease type C (NPC), IB1001-202 for GM2 gangliosidoses (Tay-Sachs and Sandhoff), IB1001-203 for ataxia telangiectasia (A-T)) have been registered at www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39), and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511).
Collapse
Affiliation(s)
- T. Fields
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - M. Patterson
- Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA
| | - T. Bremova-Ertl
- Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland
| | - G. Belcher
- PV Consultancy, 113 St Georges Square Mews, London, SW1V 3RZ UK
| | - I. Billington
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - G. C. Churchill
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT UK
| | - W. Davis
- Ataxia-Telangiectasia Society, Rothamsted Experimental Station West Common, Harpenden, AL5 2JQ UK
| | - W. Evans
- Niemann-Pick UK, Vermont House, Concord, Washington, Tyne and Wear NE37 2SQ UK
- Primary Care Stratified Medicine (PRISM) Division of Primary Care, University of Nottingham, Nottingham, UK
| | - S. Flint
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - A. Galione
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT UK
| | - U. Granzer
- Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 Munich, Germany
| | | | - R. Karl
- Cure Tay-Sachs Foundation, 2409 E. Luke Avenue, Phoenix, AZ 85016 USA
| | - R. Kay
- RK Statistics, Brook House, Mesne Lane, Bakewell, DE45 1AL UK
| | - D. Lewi
- The Cure & Action for Tay-Sachs Foundation, 94 Milborough Crescent, Lee, London, SE12 0RW UK
| | - T. Mathieson
- International Niemann-Pick Disease Alliance, Vermont House, Concord, Washington, Tyne and Wear NE37 2SQ UK
| | - T. Meyer
- Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 Munich, Germany
| | - D. Pangonis
- National Tay-Sachs and Allied Disease Foundation, 2001 Beacon Street, Suite 204, Boston, MA 02135 USA
| | - F. M. Platt
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT UK
| | - L. Tsang
- Arnold & Porter Kaye Scholer LLP, 25 Old Broad Street, London, EC2N 1HQ UK
| | - C. Verburg
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - M. Factor
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - M. Strupp
- Department of Neurology and German Center for Vertigo and Balance Disorders, University Hospital, Ludwig Maximilians University, Munich, Germany
| |
Collapse
|
4
|
Joberty G, Boesche M, Brown JA, Eberhard D, Garton NS, Humphreys PG, Mathieson T, Muelbaier M, Ramsden NG, Reader V, Rueger A, Sheppard RJ, Westaway SM, Bantscheff M, Lee K, Wilson DM, Prinjha RK, Drewes G. Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics. ACS Chem Biol 2016; 11:2002-10. [PMID: 27197014 DOI: 10.1021/acschembio.6b00080] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The 2-oxoglutarate-dependent dioxygenase target class comprises around 60 enzymes including several subfamilies with relevance to human disease, such as the prolyl hydroxylases and the Jumonji-type lysine demethylases. Current drug discovery approaches are largely based on small molecule inhibitors targeting the iron/2-oxoglutarate cofactor binding site. We have devised a chemoproteomics approach based on a combination of unselective active-site ligands tethered to beads, enabling affinity capturing of around 40 different dioxygenase enzymes from human cells. Mass-spectrometry-based quantification of bead-bound enzymes using a free-ligand competition-binding format enabled the comprehensive determination of affinities for the cosubstrate 2-oxoglutarate and for oncometabolites such as 2-hydroxyglutarate. We also profiled a set of representative drug-like inhibitor compounds. The results indicate that intracellular competition by endogenous cofactors and high active site similarity present substantial challenges for drug discovery for this target class.
Collapse
Affiliation(s)
- Gérard Joberty
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Markus Boesche
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Jack A. Brown
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Dirk Eberhard
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Neil S. Garton
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Philip G. Humphreys
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Toby Mathieson
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Marcel Muelbaier
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Nigel G. Ramsden
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Valérie Reader
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Anne Rueger
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Robert J. Sheppard
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Susan M. Westaway
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Marcus Bantscheff
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| | - Kevin Lee
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - David M. Wilson
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Rab K. Prinjha
- Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom
| | - Gerard Drewes
- Cellzome GmbH, a GlaxoSmithKline company, Meyerhofstrasse 1, Heidelberg, Germany
| |
Collapse
|
5
|
Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Huspenina J, Boese JH, Bantscheff M, Gerstmair A, Faerber F, Kuster B. Mass-spectrometry-based draft of the human proteome. Nature 2014; 509:582-7. [PMID: 24870543 DOI: 10.1038/nature13319] [Citation(s) in RCA: 1321] [Impact Index Per Article: 132.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2013] [Accepted: 04/11/2014] [Indexed: 12/15/2022]
Abstract
Proteomes are characterized by large protein-abundance differences, cell-type- and time-dependent expression patterns and post-translational modifications, all of which carry biological information that is not accessible by genomics or transcriptomics. Here we present a mass-spectrometry-based draft of the human proteome and a public, high-performance, in-memory database for real-time analysis of terabytes of big data, called ProteomicsDB. The information assembled from human tissues, cell lines and body fluids enabled estimation of the size of the protein-coding genome, and identified organ-specific proteins and a large number of translated lincRNAs (long intergenic non-coding RNAs). Analysis of messenger RNA and protein-expression profiles of human tissues revealed conserved control of protein abundance, and integration of drug-sensitivity data enabled the identification of proteins predicting resistance or sensitivity. The proteome profiles also hold considerable promise for analysing the composition and stoichiometry of protein complexes. ProteomicsDB thus enables navigation of proteomes, provides biological insight and fosters the development of proteomic technology.
Collapse
Affiliation(s)
- Mathias Wilhelm
- 1] Chair of Proteomics and Bioanalytics, Technische Universität München, Emil-Erlenmeyer Forum 5, 85354 Freising, Germany [2] SAP AG, Dietmar-Hopp-Allee 16, 69190 Walldorf, Germany [3]
| | - Judith Schlegl
- 1] SAP AG, Dietmar-Hopp-Allee 16, 69190 Walldorf, Germany [2]
| | - Hannes Hahne
- 1] Chair of Proteomics and Bioanalytics, Technische Universität München, Emil-Erlenmeyer Forum 5, 85354 Freising, Germany [2]
| | - Amin Moghaddas Gholami
- 1] Chair of Proteomics and Bioanalytics, Technische Universität München, Emil-Erlenmeyer Forum 5, 85354 Freising, Germany [2]
| | | | | | | | - Lars Butzmann
- SAP AG, Dietmar-Hopp-Allee 16, 69190 Walldorf, Germany
| | | | - Harald Marx
- Chair of Proteomics and Bioanalytics, Technische Universität München, Emil-Erlenmeyer Forum 5, 85354 Freising, Germany
| | - Toby Mathieson
- Cellzome GmbH, Meyerhofstraße 1, 69117 Heidelberg, Germany
| | - Simone Lemeer
- Chair of Proteomics and Bioanalytics, Technische Universität München, Emil-Erlenmeyer Forum 5, 85354 Freising, Germany
| | | | - Ulf Reimer
- JPT Peptide Technologies GmbH, Volmerstraße 5, 12489 Berlin, Germany
| | - Holger Wenschuh
- JPT Peptide Technologies GmbH, Volmerstraße 5, 12489 Berlin, Germany
| | - Martin Mollenhauer
- Institute of Pathology, Technische Universität München, Trogerstraße 18, 81675 München, Germany
| | - Julia Slotta-Huspenina
- Institute of Pathology, Technische Universität München, Trogerstraße 18, 81675 München, Germany
| | | | | | | | - Franz Faerber
- SAP AG, Dietmar-Hopp-Allee 16, 69190 Walldorf, Germany
| | - Bernhard Kuster
- 1] Chair of Proteomics and Bioanalytics, Technische Universität München, Emil-Erlenmeyer Forum 5, 85354 Freising, Germany [2] Center for Integrated Protein Science Munich, Germany
| |
Collapse
|
6
|
Werner T, Sweetman G, Savitski MF, Mathieson T, Bantscheff M, Savitski MM. Ion coalescence of neutron encoded TMT 10-plex reporter ions. Anal Chem 2014; 86:3594-601. [PMID: 24579773 DOI: 10.1021/ac500140s] [Citation(s) in RCA: 174] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Isobaric mass tag-based quantitative proteomics strategies such as iTRAQ and TMT utilize reporter ions in the low mass range of tandem MS spectra for relative quantification. The recent extension of TMT multiplexing to 10 conditions has been enabled by utilizing neutron encoded tags with reporter ion m/z differences of 6 mDa. The baseline resolution of these closely spaced tags is possible due to the high resolving power of current day mass spectrometers. In this work we evaluated the performance of the TMT10 isobaric mass tags on the Q Exactive Orbitrap mass spectrometers for the first time and demonstrated comparable quantification accuracy and precision to what can be achieved on the Orbitrap Elite mass spectrometers. However, we discovered, upon analysis of complex proteomics samples on the Q Exactive Orbitrap mass spectrometers, that the proximate TMT10 reporter ion pairs become prone to coalescence. The fusion of the different reporter ion signals into a single measurable entity has a detrimental effect on peptide and protein quantification. We established that the main reason for coalescence is the commonly accepted maximum ion target for MS2 spectra of 1e6 on the Q Exactive instruments. The coalescence artifact was completely removed by lowering the maximum ion target for MS2 spectra from 1e6 to 2e5 without any losses in identification depth or quantification quality of proteins.
Collapse
Affiliation(s)
- Thilo Werner
- Cellzome GmbH , Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
7
|
Savitski MM, Mathieson T, Zinn N, Sweetman G, Doce C, Becher I, Pachl F, Kuster B, Bantscheff M. Measuring and Managing Ratio Compression for Accurate iTRAQ/TMT Quantification. J Proteome Res 2013; 12:3586-98. [DOI: 10.1021/pr400098r] [Citation(s) in RCA: 189] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
| | - Toby Mathieson
- Cellzome GmbH, Meyerhofstrasse 1, 69117
Heidelberg, Germany
| | - Nico Zinn
- Cellzome GmbH, Meyerhofstrasse 1, 69117
Heidelberg, Germany
| | | | - Carola Doce
- Cellzome GmbH, Meyerhofstrasse 1, 69117
Heidelberg, Germany
| | | | - Fiona Pachl
- Chair
of Proteomics and Bioanalytics, Technische Universität München, Emil
Erlenmeyer Forum 5, 85354 Freising, Germany
| | - Bernhard Kuster
- Chair
of Proteomics and Bioanalytics, Technische Universität München, Emil
Erlenmeyer Forum 5, 85354 Freising, Germany
- Center for Integrated Protein Sciences Munich (CIPSM), Butenandtstrasse 5-13,
81377 Munich, Germany
| | | |
Collapse
|
8
|
Clare SE, Pardo I, Mathieson T, Lillemoe HA, Blosser RJ, Choi M, Sauder CAM, Doxey DK, Badve S, Storniolo AMV, Atale R, Radovich M. Abstract P1-03-02: “Normal” tissue adjacent to breast cancer is not normal. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-03-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Gene expression data from pancreatic cancer, histologically normal tissue adjacent to the cancer and normal pancreas reveals that adjacent normal has already acquired a number of transcriptional alterations and is not, therefore, an appropriate baseline for comparison with cancers. (Gadaleta et al., 2011) The purpose of this study was to determine if this is also the case for breast cancer and, if so, to identify the differences in gene expression between adjacent normal and normal breast.
Methods: RNA-Seq data from breast cancer and adjacent normal was downloaded from the TCGA (The Cancer Genome Atlas) data portal. The epithelia from 20 frozen tissue cores from healthy premenopausal donors to the Susan G. Komen for the the Cure® Tissue Bank at the IU Simon Cancer Center were microdissected and the RNA isolated. RNA-seqeuncing was carried out using the Life Technologies SOLiD Platform. RPKM gene expression values from TCGA and sequencing of the Komen normal tissues were merged, quantile normalized, and batch effect corrected. Normalization and differential gene expression was performed using Partek Genomics Suite.
Results: Principal component analysis (PCA) reveals complete separation between adjacent normal and healthy normal breast tissue. Setting a maximum FDR (false discover rate) of 5%, 2239 genes are differentially expressed between adjacent normal and healthy normal. Ingenuity pathway analysis reveals that the Fos, Jun and TGFbeta pathways are active in the adjacent normal.
Conclusions: Tissue adjacent to a primary breast cancer is not normal when using healthy breast tissue as a comparator. As RNA-Seq data is digital, it is possible to quantify the changes in gene expression starting from healthy normal to normal adjacent to tumor to tumor. Increasing and decreasing gene expression values provide clues to the fundamental molecular changes occurring in histologically normal appearing adjacent tissue. The differences in gene expression we have identified are some of the earliest changes in breast carcinogenesis and provide insight into the etiology of this disease and, potentially, its prevention.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-03-02.
Collapse
Affiliation(s)
- SE Clare
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - I Pardo
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - T Mathieson
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - HA Lillemoe
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - RJ Blosser
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - M Choi
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - CAM Sauder
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - DK Doxey
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - S Badve
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - AMV Storniolo
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - R Atale
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| | - M Radovich
- Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
9
|
Urbaniak MD, Mathieson T, Bantscheff M, Eberhard D, Grimaldi R, Miranda-Saavedra D, Wyatt P, Ferguson MAJ, Frearson J, Drewes G. Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei. ACS Chem Biol 2012; 7:1858-65. [PMID: 22908928 PMCID: PMC3621575 DOI: 10.1021/cb300326z] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The protozoan parasite Trypanosoma brucei is the causative agent of African sleeping sickness, and there is an urgent unmet need for improved treatments. Parasite protein kinases are attractive drug targets, provided that the host and parasite kinomes are sufficiently divergent to allow specific inhibition to be achieved. Current drug discovery efforts are hampered by the fact that comprehensive assay panels for parasite targets have not yet been developed. Here, we employ a kinase-focused chemoproteomics strategy that enables the simultaneous profiling of kinase inhibitor potencies against more than 50 endogenously expressed T. brucei kinases in parasite cell extracts. The data reveal that T. brucei kinases are sensitive to typical kinase inhibitors with nanomolar potency and demonstrate the potential for the development of species-specific inhibitors.
Collapse
Affiliation(s)
- Michael D. Urbaniak
- Division of
Biological Chemistry
and Drug Discovery, College of Life Sciences, University
of Dundee, Dow Street, Dundee DD1 5EH, U.K
- E-mail: ;
| | - Toby Mathieson
- Cellzome AG, Meyerhofstrasse 1, D-69117 Heidelberg, Germany
| | | | - Dirk Eberhard
- Cellzome AG, Meyerhofstrasse 1, D-69117 Heidelberg, Germany
| | - Raffaella Grimaldi
- Division of
Biological Chemistry
and Drug Discovery, College of Life Sciences, University
of Dundee, Dow Street, Dundee DD1 5EH, U.K
| | - Diego Miranda-Saavedra
- World Premier International Immunology
Frontier Research Centre, Osaka University, 3-1 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Paul Wyatt
- Division of
Biological Chemistry
and Drug Discovery, College of Life Sciences, University
of Dundee, Dow Street, Dundee DD1 5EH, U.K
| | - Michael A. J. Ferguson
- Division of
Biological Chemistry
and Drug Discovery, College of Life Sciences, University
of Dundee, Dow Street, Dundee DD1 5EH, U.K
| | - Julie Frearson
- BioFocus, Chesterford
Park, Saffron Walden, Essex CB10 1XL, U.K
| | - Gerard Drewes
- Cellzome AG, Meyerhofstrasse 1, D-69117 Heidelberg, Germany
- E-mail: ;
| |
Collapse
|
10
|
Bergamini G, Bell K, Shimamura S, Werner T, Cansfield A, Müller K, Perrin J, Rau C, Ellard K, Hopf C, Doce C, Leggate D, Mangano R, Mathieson T, O'Mahony A, Plavec I, Rharbaoui F, Reinhard F, Savitski MM, Ramsden N, Hirsch E, Drewes G, Rausch O, Bantscheff M, Neubauer G. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nat Chem Biol 2012; 8:576-82. [PMID: 22544264 DOI: 10.1038/nchembio.957] [Citation(s) in RCA: 121] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2012] [Accepted: 04/02/2012] [Indexed: 01/18/2023]
Abstract
We devised a high-throughput chemoproteomics method that enabled multiplexed screening of 16,000 compounds against native protein and lipid kinases in cell extracts. Optimization of one chemical series resulted in CZC24832, which is to our knowledge the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target- and cell-based profiling of CZC24832 revealed regulation of interleukin-17-producing T helper cell (T(H)17) differentiation by PI3Kγ, thus reinforcing selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases.
Collapse
|
11
|
Clare SE, Mathieson T, Henry JE, Zhang H, Way ES, Ridley KE, Badve S, Herbert BS, Rufenbarger CA, Storniolo AMV. P5-21-02: The Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center: The Source for Normal Breast Tissue and Biospecimens. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-21-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. This ignorance has been the consequence of the lack of access to richly annotated, high quality normal breast specimens. The Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center (KTB) was established expressly to remedy this deficiency. The KTB is a repository of specimens from volunteer donors with no clinical evidence of breast malignancy. The Bank's mission is to make available specimens that will enable an understanding of the developmental biology of the normal breast, to provide insight into breast oncogenesis, and to provide a normal control for breast cancer research. The purpose of this presentation is to increase the awareness of this unique and rich research resource and to actively solicit the use of its specimens.
Methods: The KTB has been prospectively banking fresh frozen breast tissue since mid-2006. Coincident with the tissue donation two tubes of blood are obtained, which are processed for lymphocyte DNA, serum and plasma. These specimens are richly annotated with detailed information regarding the donors’ reproductive history, medical history, family history, and medications. Standard Operating Procedures have been constructed so as to control, limit and identify potential sources of bias. All of this information is recorded in an Oracle-based, searchable database.
Results: As of June 2011, the KTB and its predecessor bank, Mary Ellen's Bank, have available fresh frozen breast tissue (10 gauge cores) from 1469 donors; formalin-fixed, paraffin-embedded tissue from 1055; DNA from 7507; serum from 2382; and plasma from 3771 donors. The KTB has also established 28 epithelial and 33 stromal cell lines from the cores; 4 of the epithelial cell lines have been immortalized using hTERT. Donors range in age from 18–86 years of age. 9% of donors to the KTB describe themselves as Hispanic/Latino. 5.2% of donors are Black or African-American. Using the Gail Risk Model, there is a bimodal distribution of life-time breast cancer risk among the donors: the largest peak is at 10% and a smaller one at 18%.
Conclusions: The KTB is a unique and invaluable research resource which is now open for business and accessible to researchers across the globe. We encourage researchers to avail themselves of this unique tissue resource and to also acquaint themselves with other sources of healthy breast tissue, i.e., the Love/Avon Army of Women [http://www.armyofwomen.org/].
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-21-02.
Collapse
Affiliation(s)
- SE Clare
- 1Indiana University School of Medicine, Indianapolis, IN
| | - T Mathieson
- 1Indiana University School of Medicine, Indianapolis, IN
| | - JE Henry
- 1Indiana University School of Medicine, Indianapolis, IN
| | - H Zhang
- 1Indiana University School of Medicine, Indianapolis, IN
| | - ES Way
- 1Indiana University School of Medicine, Indianapolis, IN
| | - KE Ridley
- 1Indiana University School of Medicine, Indianapolis, IN
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN
| | - B-S Herbert
- 1Indiana University School of Medicine, Indianapolis, IN
| | - CA Rufenbarger
- 1Indiana University School of Medicine, Indianapolis, IN
| | - AMV Storniolo
- 1Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
12
|
Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dümpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011; 29:255-65. [PMID: 21258344 DOI: 10.1038/nbt.1759] [Citation(s) in RCA: 495] [Impact Index Per Article: 38.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2010] [Accepted: 12/17/2010] [Indexed: 11/09/2022]
Abstract
The development of selective histone deacetylase (HDAC) inhibitors with anti-cancer and anti-inflammatory properties remains challenging in large part owing to the difficulty of probing the interaction of small molecules with megadalton protein complexes. A combination of affinity capture and quantitative mass spectrometry revealed the selectivity with which 16 HDAC inhibitors target multiple HDAC complexes scaffolded by ELM-SANT domain subunits, including a novel mitotic deacetylase complex (MiDAC). Inhibitors clustered according to their target profiles with stronger binding of aminobenzamides to the HDAC NCoR complex than to the HDAC Sin3 complex. We identified several non-HDAC targets for hydroxamate inhibitors. HDAC inhibitors with distinct profiles have correspondingly different effects on downstream targets. We also identified the anti-inflammatory drug bufexamac as a class IIb (HDAC6, HDAC10) HDAC inhibitor. Our approach enables the discovery of novel targets and inhibitors and suggests that the selectivity of HDAC inhibitors should be evaluated in the context of HDAC complexes and not purified catalytic subunits.
Collapse
|
13
|
Clare SE, Pardo I, Mathieson T, Lillemoe HA, Goulet RJ, Henry JE, Sun J, Mitchum P, Parsons E, Jackson VP, Rager EL, Kennedy PR, Willimas-Bowling M, Savader B, Westphal SM, Pennington RE, Walker KH, Ritter HE, Berg RC, Bangs R, Badve S, Liu Y, Radovich M, Rufenbarger CA, Storniolo AMV. Abstract P6-04-01: Next-Generation Transcriptome Sequencing of the Normal Breast. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center (KTB) was established expressly to address and remedy this deficiency. The KTB acquires and banks normal breast tissue, that is, breast tissue from volunteer donors with no clinical evidence of breast malignancy. This tissue is NOT from reduction mammoplasties or from histologically normal tissue adjacent to a malignancy.
The breast is one of the most complex genetic organs within the body. This is because the expression of its genes is under the control and influence of the hormonal milieu present in the circulating plasma, which changes as a function of age; for premenopausal women as a function of the menstrual cycle; and as a consequence of pregnancy. Therefore, there is unlikely to be a singular “normal” breast. We propose to produce a molecular encyclopedia of the normal breast which covers the entire spectrum of normal: puberty to menopause, low risk to high risk, nulliparous and parous.
Materials and Methods: The epithelial compartment of fresh frozen tissue from 10 premenopausal donors to the KTB, 5 women who were in the follicular phase of the menstrual cycle and 5 who were in the luteal, was isolated using laser capture microdissection. Total RNA extracted from the cells was subsequently depleted for ribosomal RNA. RNA was sequenced on an Applied Biosystems SOLiD3 sequencer using 50bp runs. Reads were mapped to the human genome. Whole blood was collected at the time of tissue donation and uniformly processed into serum. Results: RNA sequencing of the 10 samples produced 596 million reads of which 386 million (62%) mapped to the human genome. Setting the p-value at <0.05 for the comparison of follicular versus luteal, there were 3395 differentially expressed RefSeq genes, 35 differentially expressed premiRNAs, 297 differentially expressed lincRNA exons and 40 differentially expressed UCRs (Ultra Conserved Regions). There were 1394 novel transcribed regions which were significantly differentially expressed. The serum estradiol at the time of donation was determined for 9 of the 10 donors. The gene expression of 901 genes was strongly correlated with serum estradiol concentration.
Proliferating Cell Nuclear Antigen (PCNA), nucleosome assembly genes and genes involved with mitosis have greater expression during the luteal phase of the menstrual cycle. Genes associated with development, e.g., NOTCH2, PAX3, DKK3 and TWIST1, are more abundantly expressed during the follicular phase. Many of the differentially expressed genes have been implicated in breast oncogenesis.
Conclusions: The Komen Tissue Bank has completed the first ever next-generation transcriptome sequencing of epithelial compartment of ten normal human breast specimens. This work has produced the most comprehensive catalog to date of the differences in the expression of protein encoding genes, pre-miRNAs, lincRNA exons, UCRs and novel transcribed regions as a function of the phase of the menstrual cycle. Additionally, this effort has identified a relatively significant number of genes whose expression is very likely under the control of estrogen.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-04-01.
Collapse
Affiliation(s)
- SE Clare
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - I Pardo
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - T Mathieson
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - HA Lillemoe
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - RJ Goulet
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - JE Henry
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - J Sun
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - P Mitchum
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - E Parsons
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - VP Jackson
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - EL Rager
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - PR Kennedy
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - M Willimas-Bowling
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - B Savader
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - SM Westphal
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - RE Pennington
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - KH Walker
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - HE Ritter
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - RC Berg
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - R Bangs
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - S Badve
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - Y Liu
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - M Radovich
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - CA Rufenbarger
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| | - AMV. Storniolo
- Indiana Univeristy School of Medicine, Indianapolis; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN; Clarian Arnett Cancer Center, Lafayette, IN; Indiana University School of Medicine, Indianapolis
| |
Collapse
|
14
|
Radovich M, Clare SE, Sledge GW, Pardo I, Mathieson T, Kassem N, Hancock BA, Storniolo AMV, Rufenbarger C, Lillemoe HA, Sun J, Henry JE, Goulet R, Hilligoss EE, Siddiqui AS, Breu H, Sakarya O, Hyland FC, Muller MW, Popescu L, Zhu J, Hickenbotham M, Glasscock J, Ivan M, Liu Y, Schneider BP. Abstract PD01-08: Decoding the Transcriptional Landscape of Triple-Negative Breast Cancer Using Next-Generation Whole Transcriptome Sequencing. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) has been plagued by the absence of targeted therapies. Discovery of therapeutic targets in TNBC has in part, been hampered by an inadequate understanding of the transcriptional biology of the normal breast as an optimal comparator. Using next-generation sequencing, we embarked on a study to compare the transcriptomes of TNBC and normal breast to comprehensively identify novel targets by analyzing all full length transcripts expressed in these tissues.
Methods: Normal breast tissues from healthy pre-menopausal volunteers with no history of disease were procured from the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center. To eliminate bias from stromal tissue, normal tissues were laser capture microdissected for ductal epithelium. cDNA libraries from 10 TNBC tumors and 10 normal breast tissues were sequenced on an Applied Biosystems (AB) SOLiD3 sequencer using 50bp fragment runs. For gene expression, mapping of reads to the genome was performed using the AB BioScope 1.2 Pipeline and outputs imported into Partek Genomics Suite for analysis. In Partek, mapped reads were cross-referenced against known genes from the UCSC database followed by statistical comparison of RPKM values for each gene between TNBC and normal. Dimensionality reduction analyses (PCA & Hierarchical clustering) and identification of Novel Transcribed Regions were also performed in Partek, whereas construction of gene networks was performed using Ingenuity Pathway Analysis. To identify gene fusions, partially mapped reads were interrogated utilizing a novel algorithm that searched for reads spanning exons from two different genes. Fusions that were supported by at least 3 reads (of which 2 had to be unique) were considered candidates and were subsequently validated. Results/Discussion: Sequencing produced 1.1 billion reads equaling 57.3GB of data of which 36.0GB (63%) mapped to the human genome. In comparing RPKM values between TNBC and Normal, we report 7140 RefSeq Genes, 22 pre-miRNAs, 109 lincRNA exons, and 15 ultraconserved regions that were differentially expressed between these tissues (FDR<0.01). Biological interpretation of these results reveals upregulation of genes and miRNAs involved in DNA repair, angiogenesis, and inhibitors of Estrogen Receptor-alpha. Some previous drug targets (e.g. EGFR and c-kit) were not found to be upregulated here which may explain lack of clinical success to date. Conversely, PARP was significantly upregulated and early trial results suggest a strong signal for efficacy with inhibition of PARP. We also surveyed the genome for Novel Transcribed Regions (NTRs), defined as areas of significant transcription where no annotated gene is present. When comparing between TNBC and Normal, we report 6408 NTRs to be differentially expressed (FDR<0.01). Lastly, when analyzing the dataset for gene fusions, we identified several gene fusions in the TNBC samples, though no individual fusion was present in more than one sample.
Conclusion: We report an extensive comparison of the transcriptomes of TNBC and normal ductal epithelium. We identified numerous genes previously unknown to be dysregulated in TNBC that can be utilized for therapeutic discovery.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD01-08.
Collapse
Affiliation(s)
- M Radovich
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - SE Clare
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - GW Sledge
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - I Pardo
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - T Mathieson
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - N Kassem
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - BA Hancock
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - AMV Storniolo
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - C Rufenbarger
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - HA Lillemoe
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - J Sun
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - JE Henry
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - R Goulet
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - EE Hilligoss
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - AS Siddiqui
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - H Breu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - O Sakarya
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - FC Hyland
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - MW Muller
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - L Popescu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - J Zhu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - M Hickenbotham
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - J Glasscock
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - M Ivan
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - Y Liu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - BP. Schneider
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| |
Collapse
|
15
|
Savitski MM, Lemeer S, Boesche M, Lang M, Mathieson T, Bantscheff M, Kuster B. Confident phosphorylation site localization using the Mascot Delta Score. Mol Cell Proteomics 2010; 10:M110.003830. [PMID: 21057138 DOI: 10.1074/mcp.m110.003830] [Citation(s) in RCA: 222] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Large scale phosphorylation analysis is more and more getting into focus of proteomic research. Although it is now possible to identify thousands of phosphorylated peptides in a biological system, confident site localization remains challenging. Here we validate the Mascot Delta Score (MD-score) as a simple method that achieves similar sensitivity and specificity for phosphosite localization as the published Ascore, which is mainly used in conjunction with Sequest. The MD-score was evaluated using liquid chromatography-tandem MS data of 180 individually synthesized phosphopeptides with precisely known phosphorylation sites. We tested the MD-score for a wide range of commonly available fragmentation methods and found it to be applicable throughout with high statistical significance. However, the different fragmentation techniques differ strongly in their ability to localize phosphorylation sites. At 1% false localization rate, the highest number of correctly assigned phosphopeptides was achieved by higher energy collision induced dissociation in combination with an Orbitrap mass analyzer followed very closely by low resolution ion trap spectra obtained after electron transfer dissociation. Both these methods are significantly better than low resolution spectra acquired after collision induced dissociation and multi stage activation. Score thresholds determined from simple calibration functions for each fragmentation method were stable over replicate analyses of the phosphopeptide set. The MD-score outperforms the Ascore for tyrosine phosphorylated peptides and we further show that the ability to call sites correctly increases with increasing distance of two candidate sites within a peptide sequence. The MD-score does not require complex computational steps which makes it attractive in terms of practical utility. We provide all mass spectra and the synthetic peptides to the community so that the development of present and future localization software can be benchmarked and any laboratory can determine MD-scores and localization probabilities for their individual analytical set up.
Collapse
|
16
|
Savitski MM, Scholten A, Sweetman G, Mathieson T, Bantscheff M. Evaluation of Data Analysis Strategies for Improved Mass Spectrometry-Based Phosphoproteomics. Anal Chem 2010; 82:9843-9. [DOI: 10.1021/ac102083q] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
| | - Arjen Scholten
- Cellzome AG, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | | | - Toby Mathieson
- Cellzome AG, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | | |
Collapse
|
17
|
Savitski MM, Fischer F, Mathieson T, Sweetman G, Lang M, Bantscheff M. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. J Am Soc Mass Spectrom 2010; 21:1668-1679. [PMID: 20171116 DOI: 10.1016/j.jasms.2010.01.012] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2009] [Revised: 01/13/2010] [Accepted: 01/13/2010] [Indexed: 05/28/2023]
Abstract
Quantitative mass spectrometry-based proteomic assays often suffer from a lack of robustness and reproducibility. We here describe a targeted mass spectrometric data acquisition strategy for affinity enriched subproteomes-in our case the kinome-that enables a substantially improved reproducibility of detection, and improved quantification via isobaric tags. Inclusion mass lists containing m/z, charge state, and retention time were created based on a set of 80 shotgun-type experiments performed under identical experimental conditions. For each target protein, peptides were selected according to their frequency of observation and isobaric tag for relative and absolute quantitation (iTRAQ) reporter ion quality. Retention times of selected peptides were aligned using similarity driven pairwise alignment strategy yielding <1 min standard deviation for 4 h gradients. Multiple fragmentation of the same peptides resulted in better statistics and more precise reporter ion based quantification without any loss in coverage. Overall, 24% more target proteins were quantified using the targeted data acquisition approach, and precision of quantification improved by >1.5-fold. We also show that a combination of higher energy collisional dissociation (HCD) with collisional induced dissociation (CID) outperformed pulsed-Q-dissociation (PQD) on the OrbitrapXL. With the CID/HCD based targeted data acquisition approach 10% more quantifiable target proteins were identified and a 2-fold increase in quantification precision was achieved. We have observed excellent reproducibility between different instruments, underlining the robustness of the approach.
Collapse
|
18
|
Savitski MM, Mathieson T, Becher I, Bantscheff M. H-score, a mass accuracy driven rescoring approach for improved peptide identification in modification rich samples. J Proteome Res 2010; 9:5511-6. [PMID: 20836569 DOI: 10.1021/pr1006813] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Currently, scoring algorithms of many popular search engines for tandem mass spectrometry (MS/MS) data only partially utilize the information content of high mass accuracy MS/MS data. We have developed a new rescoring scheme, H-score, that employs high mass accuracy matching of all detected fragment ions to candidate peptide sequences in an abundance independent fashion. Peptides for which b or y ions are found for all or almost all backbone fragmentation sites are rewarded. For peptide hits generated by Mascot, rescoring proved to be particularly beneficial when applied on samples containing many different potential modifications. For a histone sample acquired on an Orbitrap Velos using HCD for peptide fragmentation, the H-score identified 24% more spectra at 0.01 false positive rate than Mascot scoring of spectra processed according to state-of-the-art methods and 61% better than Mascot scoring of unprocessed MS/MS spectra. For a low-abundance sample, where many weak spectra were detected, these numbers went up to 53 and 190%, respectively. When applied on a kinase-enriched sample containing only a few modifications, a smaller but still significant gain of 5% was observed.
Collapse
|
19
|
Clare S, Sun J, Henry J, Mathieson T, Mitchum P, Badve S, Rufenbarger C, Rufenbarger C, Storniolo A. The Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center: The Source for Normal Breast Tissue and Biospecimens. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. This ignorance has been the consequence of the lack of access to richly annotated, high quality normal breast specimens. To provide the specimens that will enable the study of normal mammary development and to provide normal controls for breast cancer research, the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center (KTB) was established. The KTB is a repository of specimens from volunteer donors with no clinical evidence of breast malignancy. The purpose of this presentation is to increase the awareness of this unique and rich research resource and to actively solicit the use of its specimens.Methods: The initial collection venue was the 2005 Komen Indianapolis Race for the Cure® at which whole blood was collected, and processed for DNA. The collection of serum began one year later. The KTB has been prospectively banking fresh frozen breast tissue since mid-2006. Plasma processing began in 2008. These specimens are richly annotated with detailed information regarding the donors' reproductive history, medical history, family history, and medications. Standard Operating Procedures have been constructed so as to control, limit and identify potential sources of bias. All of this information is recorded in an Oracle-based, searchable database.There are five, straight-forward steps to submit a proposal for specimen access: 1. Generate a hypothesis and design a study to test the hypothesis; 2. Perform a preliminary statistical analysis to determine the number of samples needed to test the hypothesis; 3. Access the Komen Tissue Bank on-line and determine if the Bank has the type and number of specimens to fulfill your research needs. A sample/data search can be performed on-line at https://komentissuebank.iu.edu/search; 4. Obtain IRB approval from your institution and secure funding for your research project; 5. Submit your proposal to the KTB using the on-line form. Deadlines are February 1, June 15 and October 15 yearly. Proposals are reviewed by the Proposal Review Committee, composed of internal and external scientific experts and patient advocates. Additional information can be found on the KTB website: https://komentissuebank.iu.edu/research.Results: As of June 2009, the KTB and its predecessor bank, Mary Ellen's Bank, have available fresh frozen breast tissue (10 gauge cores) from 508 individual donors, DNA from 2524, serum from 1360 and plasma from 1438 donors.Figure 1 Life-time risk of the development of breast cancer calculated using the Gail Model for tissue donors to the KTB. x-axis: % lifetime risk, y-axis number of tissue donors, each line =10Conclusions: The KTB is a unique and invaluable research resource which is now open for business and accessible to researchers across the globe. We encourage researchers to avail themselves of this unique tissue resource and to also acquaint themselves with other sources of healthy breast tissue, i.e., the Love/Avon Army of Women [http://www.armyofwomen.org/].
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3076.
Collapse
Affiliation(s)
| | - J. Sun
- 3 The Susan G Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - J. Henry
- 3 The Susan G Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - T. Mathieson
- 3 The Susan G Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - P. Mitchum
- 3 The Susan G Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | - C. Rufenbarger
- 3 The Susan G Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | | |
Collapse
|
20
|
Radovich M, Clare S, Clare S, Pardo I, Hancock B, Sledge G, Rufenbarger C, Rufenbarger C, Storniolo A, Storniolo A, Mathieson T, Mathieson T, Sun J, Sun J, Henry J, Henry J, Hilligoss E, Elliott J, Richt R, Hickenbotham M, Glasscock J, Liu Y, Schneider B. Next-Generation Whole Transcriptome Sequencing of Triple-Negative Breast Tumors and Normal Tissues. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer predominately affects pre-menopausal women and women of African-American descent and has been plagued by the absence of targeted therapies leading to poor survival. Using a new cutting edge technology, next-generation sequencing, we embarked on a study to analyze the whole transcriptomes of triple-negative tumors and normal tissues from pre-menopausal women in order to comprehensively identify new targets by analyzing all full length transcripts expressed in these tissues. This approach is independent of pre-determined gene selection as is common with microarrays, and allows for the analysis of RNA species that have not been previously profiled in breast cancer.Methods: cDNA libraries were created from RNA isolated from 8 triple-negative tumors and 2 normal breast tissues. Triple negative tumors were procured from Origene Technologies and normal breast tissues were procured from the Susan G. Komen for the Cure tissue bank at Indiana University. Normal samples were from healthy pre-menopausal volunteers with no history of disease. In order to eliminate bias from stromal tissue, normal samples were laser capture microdissected for ductal cells and RNA extracted from the excised tissue. cDNA libraries were prepared and subsequently sequenced on an Applied Biosystems (ABI) SOLiD3 sequencer using a 50bp fragment run. Mapping of whole reads to the human genome was performed using the SOLiD Analysis Pipeline Tool software (ABI) followed by a split-read alignment in order to map reads crossing exon-exon junctions. Gene expression profiles for each sample were then created and statistically compared to identify the most differentially expressed genes. In order to analyze for fusion genes, a split-read alignment of non-mapping reads to a composite transcriptome formed from previously mapped reads (clusters) was performed.Results: Sequencing of the 10 samples produced 513 million filtered reads equaling 25.66GB of data. Mapping of the reads to the genome revealed 1.14 million transcribed regions (exons). A preliminary analysis of gene expression shows 55.2% of the transcribed loci to have significant differential expression between tumor and normal. In a further analysis for gene fusions, several candidate fusions were bioinformatically detected. These are currently being reviewed and validated.Discussion: Herein we present a preliminary analysis of the transcriptomes of triple-negative breast cancers in comparison to normal tissues. A multitude of analyses are ongoing, including but not limited to: gene fusions, differentially expressed novel genes, novel transcripts, alternative splicing, intrinsic subtyping, and presence of viral genes. In addition 2 more triple-negative tumors and 8 normal samples will also be sequenced. In the current analysis, differentially expressed non-coding RNAs was highly pervasive among the samples indicating a major role of this RNA species in tumorigenesis. In addition, triple-negative breast cancers may contain fusion genes that could be “drivers” of this malignancy. Further validation of these differentially expressed RNAs and fusion genes in a larger set of samples with subsequent functional studies is planned.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6134.
Collapse
Affiliation(s)
| | - S. Clare
- 1Indiana University School of Medicine, IN,
| | - S. Clare
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - I. Pardo
- 1Indiana University School of Medicine, IN,
| | - B. Hancock
- 1Indiana University School of Medicine, IN,
| | - G. Sledge
- 1Indiana University School of Medicine, IN,
| | - C. Rufenbarger
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | | | - A. Storniolo
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | - T. Mathieson
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - J. Sun
- 1Indiana University School of Medicine, IN,
| | - J. Sun
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - J. Henry
- 1Indiana University School of Medicine, IN,
| | - J. Henry
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | | | | | | | | | - Y. Liu
- 1Indiana University School of Medicine, IN,
| | | |
Collapse
|
21
|
Abstract
Investigations into the metabolism of drugs used in aquatic animal therapy are useful for understanding the mechanisms of xenobiotic transformation systems and can aid the development of dosing regimens. This study investigated the metabolism of the synthetic anthelmintic praziquantel, which has application in helminthiasis treatment for several fish species including kingfish Seriola lalandi, a commercial aquaculture finfish species. At least 7 mono- or dihydroxylated derivatives of the parent compound were identified in kingfish after administration of a 150 mg kg(-1) oral praziquantel dose, paralleling findings in mammals. The structure of one representative mono-hydroxylated species that was prominent in the skin, muscle, liver, kidney and plasma of kingfish was investigated using fragmentation experiments; this revealed that hydroxylation of the parent molecule occurred in the tetrahydroisoquinoline region of praziquantel, analogous with mammalian metabolites, but different to that of the active mammalian metabolite (trans-4-OH-praziquantel). The implications of these findings with regard to biotransformation systems for this drug in mammals and fish are discussed.
Collapse
Affiliation(s)
- L Tubbs
- National Institute of Water and Atmospheric Research, PO Box 109 695, Auckland, New Zealand.
| | | | | |
Collapse
|
22
|
Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25:1035-44. [PMID: 17721511 DOI: 10.1038/nbt1328] [Citation(s) in RCA: 815] [Impact Index Per Article: 47.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2007] [Accepted: 07/16/2007] [Indexed: 11/08/2022]
Abstract
We describe a chemical proteomics approach to profile the interaction of small molecules with hundreds of endogenously expressed protein kinases and purine-binding proteins. This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and absolute quantification (iTRAQ). By measuring the competition with the affinity matrix, we assess the binding of drugs to their targets in cell lysates and in cells. By mapping drug-induced changes in the phosphorylation state of the captured proteome, we also analyze signaling pathways downstream of target kinases. Quantitative profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib. The data suggest that our approach is a valuable tool for drug discovery.
Collapse
|
23
|
Abstract
1. The nucleotide sequence of 5.8-S rRNA from Xenopus laevis is given; it differs by a C in equilibrium U transition at position 140 from the 5.8-S rRNA of Xenopus borealis. 2. The sequence contains two completely modified and two partially modified residues. 3. Three different 5' nucleotides are found: pU-C-G (0.4) pC-G (0.2) and pG (0.4). 4. The 3' terminus is C not U as in all other 5.8-S sequences so far determined. 5. The X. laevis sequence differs from the mammalian and turtle sequences by five and six residue changes respectively. 6. A ribonuclease-resistant hairpin loop is a principle feature of secondary structure models proposed for this molecule. 7. Sequence heterogeneity may occur at one position at a very low level (approximately 0.01) in X. laevis 5.8-S rRNA, while none was detected in X. borealis or HeLa cell 5.8-S rRNA.
Collapse
|
24
|
|
25
|
|